Skip to main content
Premium Trial:

Request an Annual Quote

ActivX and Pfizer Expand Proteomics, Drug Discovery Deal

NEW YORK, March 14 (GenomeWeb News) - ActivX, a subsidiary of Tokyo-based Koran Pharmaceutical, said today that it has renewed its agreement with Pfizer to encompass discovery to developmental stage projects across multiple research sites of Pfizer's Global Research and Development organization.

 

Under the terms of the agreement, ActivX will apply its chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, polemic profiling, compound selectivity and biological activity, and mechanisms of toxicity.

 

Financial terms of this transaction include an upfront technology access fee along with research support payments by Pfizer.

 

ActivX and Pfizer began their collaboration in February 2005.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.